1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for early-stage classical Hodgkin lymphoma (SGN35-027 Part C)
    Meeting Abstract

    Abramson, J. S.; Straus, D. J.; Bartlett, N. L.; Burke, J. M.; Lynch, R. C.; Domenech, E. D.; Hess, B.; Schuster, S. R.; Linhares, Y.; Ramchandren, R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Phase 1/2 study of TP-3654, a selective PIM1 kinase inhibitor: Preliminary data showed clinical activity and cytokine reductions in relapsed/refractory myelofibrosis patients
    Meeting Abstract

    Rein, L. A. M.; El Chaer, F.; Yuda, J.; Shimoda, K.; McCloskey, J.; Takami, A.; Haque, T.; Ichii, M.; Shirane, S.; Fukaya, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Cryopreservation changes the immune effector cell composition of peripheral blood stem cell grafts: An analysis from the DKMS and NMDP graft composition study
    Meeting Abstract

    Rücker-Braun, E.; Falk, B.; Markey, K. A.; Minderman, H.; Baldauf, H.; Heymann, N.; Uhlemann, H.; Heiduschke, L.; MacMillan, H. R.; Newell, E. W.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Validation of the composite complete response (cCR) definitions in the International Working Group (IWG) 2023 criteria in patients (pts) with higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) treated with hypomethylating agents (HMA) - A large, multicenter, retrospective analysis from the validate database
    Meeting Abstract

    Bewersdof, J. P.; Kewan, T.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Uy, G. L.; Carraway, H. E.; Desai, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Treatment effectiveness with venetoclax-based therapy after Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: An international real-world study
    Meeting Abstract

    Ghosh, N.; Lamanna, N.; Eyre, T. A.; Coombs, C. C.; Manzoor, B. S.; Brown, J. R.; Tuncer, H. H.; Ujjani, C. S.; Leslie, L. A.; Roeker, L. E.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of valemetostat monotherapy in patients with relapsed or refractory peripheral T-cell lymphomas: Primary results of the phase 2 VALENTINE-PTCL01 study
    Meeting Abstract

    Horwitz, S. M.; Izutsu, K.; Mehta-Shah, N.; Cordoba, R.; Barta, S. K.; Bachy, E.; Gritti, G.; Jacobsen, E.; Kusumoto, S.; Guillermin, Y.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Patient-reported outcomes in the phase 3 CARTITUDE-4 study of ciltacabtagene autoleucel vs standard of care in patients with lenalidomide-refractory multiple myeloma after 1-3 lines of therapy
    Meeting Abstract

    Mina, R.; Mylin, A. K.; Yokoyama, H.; Magen, H.; Alsdorf, W.; Minnema, M. C.; Shune, L.; Isufi, I.; Harrison, S. J.; Shah, U. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Ibrutinib added to standard conditioning and as consolidation therapy following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory activated-b-cell subtype diffuse large B-cell lymphoma (ABC-DLBCL): Primary analysis of the US intergroup double-blind randomized phase III study alliance A051301/BMT-CTN 1201
    Meeting Abstract

    Andreadis, C.; Bobek, O.; Hsi, E. D.; Fenske, T. S.; Geyer, S. M.; Stiff, P. J.; Hill, B. T.; Horwitz, M.; Khimani, F.; Little, R. F.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Multicenter, real-world study in patients with R/R large B- cell lymphoma (LBCL) who received lisocabtagene maraleucel (liso-cel) in the United States (US)
    Meeting Abstract

    Crombie, J. L.; Nastoupil, L. J.; Andreadis, C.; Isufi, I.; Hunter, B.; Winter, A.; Hess, B.; Barta, S. K.; Frigault, M. J.; Palomba, M. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • With up to 8 years of therapy, asciminib (ASC) monotherapy demonstrated continued favorable efficacy, safety, and tolerability in patients (pts) with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) without the T315I mutation: Final results from the phase 1 x2101 study
    Meeting Abstract

    Hochhaus, A.; Kim, D. W.; Cortes, J.; Sasaki, K.; Mauro, M.; Hughes, T. P.; Breccia, M.; Talpaz, M.; Minami, H.; Goh, Y. T.; more...
    Blood (2023)

    Fulltext@MSK | Save